Diabetic kidney disease: act now or pay later
- PMID: 20201761
- DOI: 10.5694/j.1326-5377.2010.tb03506.x
Diabetic kidney disease: act now or pay later
Abstract
The 21st century has the most diabetogenic environment in human history with the number of people with diabetes worldwide increasing to 380 million by 2025. The fastest rate of increase will be in developing countries. Diabetes is now the major cause of end-stage kidney disease globally; 20%-40% of people on dialysis are diabetic. In Australia, the number of people with type 2 diabetes starting dialysis increased fivefold between 1993 and 2007. We must act now at local, national and international levels to prevent type 2 diabetes; screen for early diabetic kidney disease; increase public awareness of kidney disease; treat with medications proven to reduce kidney disease progression; and promote research into and trialling of new therapies. The problem is global yet requires local action. World Kidney Day on 11 March 2010 is a time to intensify action on diabetic kidney disease and to continue to do so until this huge but largely preventable health burden is controlled.
Similar articles
-
Normalization of kidney dysfunction in normotensive, normo-albuminuric type 2 diabetes.Ren Fail. 2013 Aug;35(7):1058-9. doi: 10.3109/0886022X.2013.810541. Ren Fail. 2013. PMID: 23859540 No abstract available.
-
Controversies on the prevention of diabetic nephropathy.J Pediatr Endocrinol Metab. 1998 Apr;11 Suppl 2:365-9. J Pediatr Endocrinol Metab. 1998. PMID: 9642666 Review.
-
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.Clin Ther. 2002 Jul;24(7):1019-34. doi: 10.1016/s0149-2918(02)80016-9. Clin Ther. 2002. PMID: 12182249 Review.
-
Diabetes: Diabetic kidney disease: act now or pay later.Nat Rev Nephrol. 2010 Mar;6(3):134-6. doi: 10.1038/nrneph.2010.10. Nat Rev Nephrol. 2010. PMID: 20186229 No abstract available.
-
Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.J Cardiovasc Pharmacol. 1992;19 Suppl 6:S19-24. doi: 10.1097/00005344-199219006-00004. J Cardiovasc Pharmacol. 1992. PMID: 1382160 Review.
Cited by
-
The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.Int J Mol Sci. 2021 Sep 6;22(17):9641. doi: 10.3390/ijms22179641. Int J Mol Sci. 2021. PMID: 34502562 Free PMC article. Review.
-
Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies.Intern Emerg Med. 2024 Aug;19(5):1473-1491. doi: 10.1007/s11739-024-03700-w. Epub 2024 Jul 6. Intern Emerg Med. 2024. PMID: 38971910 Free PMC article. Review.
-
Effect of Glomerular Filtration Rate by Different Equations on Prediction Models for End-Stage Renal Disease in Diabetes.Front Endocrinol (Lausanne). 2022 Jun 3;13:873318. doi: 10.3389/fendo.2022.873318. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35721706 Free PMC article.
-
Glucose Induces IL-1α-Dependent Inflammation and Extracellular Matrix Proteins Expression and Deposition in Renal Tubular Epithelial Cells in Diabetic Kidney Disease.Front Immunol. 2020 Jul 7;11:1270. doi: 10.3389/fimmu.2020.01270. eCollection 2020. Front Immunol. 2020. PMID: 32733443 Free PMC article.
-
Global diabetic kidney disease research from 2000 to 2017: A bibliometric analysis.Medicine (Baltimore). 2019 Feb;98(6):e14394. doi: 10.1097/MD.0000000000014394. Medicine (Baltimore). 2019. PMID: 30732183 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical